SWAV

ShockWave Medical, Inc. (SWAV) | Rumor.io

ShockWave Medical

SWAV

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about SWAV?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% 0

Jun 5

$SWAV is a meme coin with a strong community, as evidenced by the numerous hearts and supportive comments.
Investors are optimistic about the potential of $SWAV, with some even adding it to their portfolios and contributing small amounts to the project.
The project's development and future prospects are being closely watched, with some commenters expressing interest in seeing how it develops and others sharing their strategies for capitalizing on its potential.

Generated by AI

Sentiment

Of the messages about SWAV that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100%	59.52% -19.28
Bearish	—	0%	0%	40.48% +19.28

Bullish· Apr 5

Johnson and Johnson is acquiring ShockWave Medical for $335 per share, providing a significant return for shareholders.
The acquisition extends Johnson and Johnson's position in cardiovascular intervention and accelerates its shift into higher-growth markets.
The deal is expected to close by mid-2024, subject to shareholder approval and regulatory approvals.

Bearish· Nov 7

* The company's results were disappointing, with the stock down -15% despite guidance that looked okay.
* The slowdown in peripheral products sales, likely due to insurance, has weighed on the stock.
* The company's decision to sell notes to raise money is seen as a negative sign, potentially weighing on the stock's price.

Generated by AI

Topics

Of the messages about SWAV that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	0%	0%	0%
Announcements	—	100%	100%	100%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	0%
Technical Analysis	—	0%	0%	0%

Earnings· Aug 7

ShockWave Medical reported Q2 2023 earnings of $0.76 per share, missing expectations by 24.75%, with revenue increasing 49% YoY to $180.2 million.
The company raised its full-year revenue guidance to $725-730 million, representing 48-49% growth over the prior year.
Gross profit margin remained steady at 86%, with gross profit increasing to $155.7 million.

Analysts· Feb 18

Morgan Stanley lowers ShockWave Medical's price target to $199 from $210, maintaining an Equal-Weight rating.
Piper Sandler lowers ShockWave Medical's price target to $245 from $272, maintaining an Overweight rating.
SVB Leerink raises ShockWave Medical's price target to $190 from $160, maintaining an Outperform rating.

Announcements· Apr 5

Johnson & Johnson is acquiring Shockwave Medical for $13.1 billion, with a deal price of $335 per share in cash.
The acquisition is expected to boost Johnson & Johnson's dominance in MedTech with Shockwave Medical's intravascular lithotripsy technology, used to treat arterial diseases.
The deal is anticipated to dilute Johnson & Johnson's adjusted earnings per share by $0.10 in 2024 and $0.17 in 2025.

Technical Analysis· Oct 25

$SWAV is making a textbook VCP and watching for a high volume breakout.
$SWAV is setting up a bull pennant with a large volume shelf, and has a strong setup on the weekly chart.
$SWAV has broken out over its 50-day moving average and trendline, and is being considered for a position in the IBD LeaderBoard.

Generated by AI

Community

Of the messages about SWAV, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	100%	60.07%
Newcomers	—	0%	0%	39.93%

Regulars· May 6

Shockwave Medical reports first-quarter 2024 earnings of $1.44 EPS and $218.81M in revenue, beating Estimize's revenue consensus by $10.22M.
The company's predictive algorithm assesses a very negative long-term outlook for Shockwave Medical, with a stock price expected to plummet quickly and dramatically.
Shockwave Medical's earnings of $1.44 EPS and $218.81M in revenue meet Estimize's consensus estimate for earnings, but beat its revenue consensus by a significant margin.

Newcomers· May 6

New investors are excited about $SWAV's strong Q1 growth, with a 36% increase in revenue and a 87% gross profit margin.
The company's proposed acquisition by Johnson & Johnson is a major concern, leading to the withdrawal of Q2 guidance.
Some traders are using options to bet on $SWAV's price, with an algorithm buying out-of-the-money calls on the stock.

Generated by AI

News

J&J raises FY26 outlook following positive Q2

Contributing around $8.9bn to its Q2 revenues of around $25.3bn, J&J MedTech’s performance was driven by its cardiovascular portfolio that includes the Shockwave IVL system.

2mo agoYahoo Finance

Also Discussed

Investors talking about SWAV also mention

#	Name	Attention
1	NARI - Inari Medical, Inc.	——
2	Lantheus Holdings Inc.LNTH	0%0
3	TransMedics Group, Inc.TMDX	0%-0.01
4	InMode Ltd.INMD	0%0
5	ABMD - Abiomed, Inc.	——
6	Medpace Holdings, Inc.MEDP	0%+0
7	AXNX - Axonics, Inc.	——
8	DMTK - DermTech, Inc.	——
9	PROCEPT BioRobotics Corp.PRCT	0%0
10	Axcelis Technologies Inc.ACLS	0%0